@prefix dc1: .
@prefix this: .
@prefix sub: .
@prefix np: .
@prefix rdf: .
@prefix nt: .
@prefix xsd: .
@prefix rdfs: .
@prefix orcid: .
@prefix bl: .
@prefix nkg: .
@prefix prov: .
@prefix npx: .
sub:Head {
this: np:hasAssertion sub:assertion;
np:hasProvenance sub:provenance;
np:hasPublicationInfo sub:pubinfo;
a np:Nanopublication .
}
sub:assertion {
bl:category bl:Disease .
sub:association rdf:object ;
rdf:predicate bl:treats;
rdf:subject ;
a rdf:Statement;
rdfs:label "pulmozyme r in cf patients with an fvc 4 of predicted daily administration of pulmozyme has also been shown to reduce the risk of respiratory tract infections requiring parenteral antibiotics pulmozyme is a recombinant dnase enzyme indicated in conjunction with standard therapies for the management of cystic fibrosis cf patients to improve pulmonary function 1";
bl:association_type bl:ChemicalToDiseaseOrPhenotypicFeatureAssociation;
bl:provided_by ;
bl:relation nkg:SymptomaticReliefIndication .
bl:category bl:Drug .
}
sub:provenance {
sub:assertion prov:wasAttributedTo orcid:0000-0002-1468-3557 .
}
sub:pubinfo {
sub:sig npx:hasAlgorithm "RSA";
npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB";
npx:hasSignature "apKQ2rdv9oREBCIc38cNFSQq39Toq5OAudEPVCF+uGJpRLVhiAZfxGfNuf4PLPGiaSy/YI/MUHZeALMqVgvgtL8zuYTxrZhANmSidCv8MkXlrKiHuzoLnyYwvbQypOuQUqXJFdZOeRO5LKL5qdUmwlnaMZbew1Wu0daUK8U0aSk=";
npx:hasSignatureTarget this: .
this: dc1:created "2021-06-12T12:30:51.524+02:00"^^xsd:dateTime;
dc1:creator orcid:0000-0002-1468-3557;
nt:wasCreatedFromProvenanceTemplate ;
nt:wasCreatedFromPubinfoTemplate ;
nt:wasCreatedFromTemplate .
}